|
🐜
|
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy
18 auth.
Y. Kang,
M. Ryu,
S. Park,
J. Kim,
J. Kim,
S. Cho,
Y. Park,
S. Park,
S. Rha,
M. Kang,
...
J. Cho,
S. Kang,
S. Roh,
B. Ryoo,
B. Nam,
Y. Jo,
K. Yoon,
S. Oh
|
5 |
2018 |
5
🐜
|
|
🐜
|
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
19 auth.
H. Park,
B. Kang,
H. Chon,
Hyeon-Su Im,
C.K. Lee,
I. Kim,
M. Kang,
J. Hwang,
W. Bae,
J. Cheon,
...
J. Park,
J. Hong,
J. Kang,
J. Kim,
S. Lim,
J. Kim,
J.W. Kim,
C. Yoo,
H. Choi
|
4 |
2021 |
4
🐜
|
|
🐜
|
55P Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)
12 auth.
C. Yoo,
K-P. Kim,
I. Kim,
M. Kang,
J. Cheon,
B. Kang,
...
H. Ryu,
J. Jeong,
J. Lee,
K. W. Kim,
B. Ryoo,
G. Abou-Alfa
|
3 |
2022 |
3
🐜
|
|
🐬
|
Incidence and management of pyrotinib-associated diarrhea in HER2-positive advanced breast cancer patients.
Chen Fang,
Jiahuai Wen,
M. Kang,
Yuzhu Zhang,
Qianjun Chen,
Liping Ren
|
2 |
2022 |
2
🐬
|
|
🐜
|
Long-term mortality of patients with tuberculosis in Korea.
7 auth.
S. Park,
M. Kang,
C. Han,
S. M. Lee,
C. J. Kim,
J. M. Lee,
...
Y. Kang
|
2 |
2020 |
2
🐜
|
|
🦁
|
6543 A phase II study of adjuvant chemotherapy with docetaxel, capecitabine and cisplatin in patients with curatively resected stage IIIb and IV advanced gastric cancer
10 auth.
M. Kang,
M. Ryu,
B. Ryoo,
Choung-Soo Kim,
B. Kang,
Se-Hoon Lee,
...
Hye-sook Chang,
J. Lee,
Tark Kim,
Y. Kang
|
0 |
2009 |
0
🦁
|
